Please login to the form below

Not currently logged in
Email:
Password:

transplant

This page shows the latest transplant news and features for those working in and with pharma, biotech and healthcare.

Viking throws downn gauntlet in NASH battle

Viking throws downn gauntlet in NASH battle

The build-up of liver fat can lead to fibrosis, cirrhosis and - in some patients - the need for a liver transplant. ... Improvements in the treatment of viral hepatitis means NASH is now expected to be the leading cause of liver transplants by 2020, and

Latest news

More from news
Approximately 9 fully matching, plus 216 partially matching documents found.

Latest Intelligence

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    That said, for thalassemia, and for sickle cell, we believe these are potentially one-time curative treatments, because these stem cell transplants have been shown to last a very long time, ... Conventional stem cell transplants cost anywhere between $500

  • Health on instalment Health on instalment

    Distasteful but…. In addition to pay-for-performance, other possible funding strategies under consideration include mandatory price limits; re-insurance (currently used for expensive transplant operations); risk pooling; and lease-like

  • Can value-based healthcare take off and reach for the skies? Can value-based healthcare take off and reach for the skies?

    way under the cost-effective price and significantly lower than the current standard of allogenic stem cell transplant that costs $500, 000-800, 000 in the first year with follow-up

  • Cell and gene therapies: on course for commercial success? Cell and gene therapies: on course for commercial success?

    Many cell therapies require additional, costly procedures for administration such as an allogeneic stem cell transplant as well as adjuvant therapies. ... Many transplant centres in England, and in other countries, are funded with a single, fixed payment

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    NASH and biosimilars. One therapeutic indication that could be seen to be gaining much attention was NASH, which is the fastest growing cause of liver cancer and liver transplant in the

More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics